Trial · NCT04679571
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 19 of 19
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mortality in both groups | 6 months | |
| Secondary | Incidence of liver-related complications in both groups | 3 months | |
| Secondary | Incidence of liver-related complications in both groups | 6 months | |
| Secondary | Incidence of liver-related complications in both groups | 12 months | |
| Secondary | Survival free of liver transplant in both groups | 6 months | |
| Secondary | Survival free of liver transplant in both groups | 12 months | |
| Secondary | Number of patients underwent TIPS (Transjugular Intrahepatic Portosystemic Shunt) in both groups | 6 months | |
| Secondary | Number of patients underwent TIPS (Transjugular Intrahepatic Portosystemic Shunt) in both groups | 12 months | |
| Secondary | Change in quality of Life as assessed by short form survey-36 version (SF-36) in both groups | 6 months | |
| Secondary | Change in quality of Life as assessed by short form survey-36 version (SF-36) in both groups | 12 months | |
| Secondary | Change in renal reserve (as assessed by renal biomarkers) in both groups | 3 months | urine NGAL, CYSTATIN C AND KIM1 will be done |
| Secondary | Change in renal reserve (as assessed by renal biomarkers) in both groups | 6 months | urine NGAL, CYSTATIN C AND KIM1 will be done |
| Secondary | Change in renal reserve (as assessed by renal biomarkers) in both groups | 12 months | urine NGAL, CYSTATIN C AND KIM1 will be done |
| Secondary | Change in the frequency of large volume paracentesis in both groups | 3 months | |
| Secondary | Change in the frequency of large volume paracentesis in both groups | 6 months | |
| Secondary | Change in the frequency of large volume paracentesis in both groups | 12 months | |
| Secondary | Improvement in pro inflammatory cytokines | 3 months | TNF ALPHA, IL6, CRP AND IL1BETA will be done |
| Secondary | Improvement in pro inflammatory cytokines | 6 months | TNF ALPHA, IL6, CRP AND IL1BETA will be done |
| Secondary | Mortality in both groups | 12 months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04679571/registered